Journal article
Omalizumab: Practical considerations regarding the risk of anaphylaxis
Abstract
Omalizumab has demonstrated efficacy among patients with moderate to severe persistent allergic asthma, whose symptoms are inadequately controlled with other controller agents. This therapy is generally well tolerated, but there are some safety considerations, the most important of which is the rare, but potentially life-threatening, occurrence of omalizumab-associated anaphylaxis.In Canada, data from the manufacturer of omalizumab indicate …
Authors
Kim HL; Leigh R; Becker A
Journal
Allergy, Asthma & Clinical Immunology, Vol. 6, No. 1,
Publisher
Springer Nature
Publication Date
12 2010
DOI
10.1186/1710-1492-6-32
ISSN
1710-1484